Prevention of infections during primary immunodeficiency

Clinical Infectious Diseases

Volumn 59, Issue 10, 2014, Pages 1462-1470

  Aguilar, Claire ^a,b,c   Malphettes, Marion ^a,d   Donadieu, Jean ^a,e   Chandesris, Olivia ^a,b,c   Coignard Biehler, Hélène ^a,b,c   Catherinot, Emilie ^a,f   Pellier, Isabelle ^a,g   Stephan, Jean Louis ^a,h   Moing, Vincent Le ^a,i   Barlogis, Vincent ^a,j   Suarez, Felipe ^a,b,c   Gérart, Stéphane ^c   Lanternier, Fanny ^a,b,c   Jaccard, Arnaud ^a,k   Consigny, Paul Henri ^b   Moulin, Florence ^b   Launay, Odile ^c   Lecuit, Marc ^a,b,c   Hermine, Olivier ^a,b,c   Oksenhendler, Eric ^a,d   Picard, Capucine ^a,b,c   Blanche, Stéphane ^a,b,c   Fischer, Alain ^a,b,c,l   Mahlaoui, Nizar ^a,b,c   Lortholary, Olivier ^a,b,c   more..

^a Centre de Référence des Déficits Immunitaires Héréditaires   (Germany)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e ARMAND TROUSSEAU HOSPITAL   (France)

^f FOCH HOSPITAL   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^h UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j TIMONE HOSPITAL   (France)

^k DUPUYTREN UNIVERSITY HOSPITAL   (France)

^l l'alimentation et l'Environnement   (France)

more..

Author keywords

Immunizations; Immunoglobulins; Primary immunodeficiency; Prophylaxis

Indexed keywords

COMPLEMENT FACTOR; STAT3 PROTEIN;

AGAMMAGLOBULINEMIA; ARTICLE; ASPLENIA; CHEMOPROPHYLAXIS; CHRONIC GRANULOMATOUS DISEASE; COMBINED IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; HUMAN; HYPER IGM SYNDROME; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOTHERAPY; INFECTION PREVENTION; INFECTIOUS COMPLICATION; MEDICAL SPECIALIST; SEVERE COMBINED IMMUNODEFICIENCY; SEVERE CONGENITAL NEUTROPENIA; COMMUNICABLE DISEASES; COMPLICATION; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFECTION; INFECTION CONTROL; PRE-EXPOSURE PROPHYLAXIS;

COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFECTION; INFECTION CONTROL; PRE-EXPOSURE PROPHYLAXIS;

EID: 84918792751     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu646     Document Type: Article

References (40)

1. Al-Herz W, Bousfiha A, Casanova J-L, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency. Front Immunol 2014;5:162.
2. ∗ guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012;18(suppl 7):53-67.
3. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000;79:170-200.
4. Blumental S, Mouy R, Mahlaoui N, et al. Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. Clin Infect Dis 2011;53:e159-69.
5. Weening RS, Kabel P, Pijman P, Roos D. Continuous therapy with sulfamethoxazoletrimethoprim in patients with chronic granulomatous disease. J Pediatr 1983;103:127-30.
6. Margolis DM, Melnick DA, Alling DW, Gallin JI. Trimethoprimsulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990;162:723-6.
7. Mouy R, Fischer A, Vilmer E, Seger R, Griscelli C. Incidence, severity, and prevention of infections in chronic granulomatous disease. J Pediatr 1989;114:555-60.
8. Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003;348:2416-22.
9. [No authors listed.] A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 1991;324:509-16.
10. Mouy R, Seger R, Bourquin JP, et al. Interferon gamma for chronic granulomatous disease. N Engl J Med 1991;325:1516-7.
11. Van Den Berg JM, Van Koppen E, Ahlin A, et al. Chronic granulomatous disease: the European experience. PLoS One 2009;4:e5234.
12. Medical Advisory Committee of the Immune Deficiency Foundation; Shearer WT, Fleisher TA, Buckley RH, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol 2014;133:961-6.
13. Donadieu J, Fenneteau O, Beaupain B, Mahlaoui N, Chantelot CB. Congenital neutropenia: diagnosis, molecular bases and patient management. Orphanet J Rare Dis 2011;6:26.
14. Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993;81:2496-502.
15. Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 2010;23:740-80.
16. Picard C, Puel A, Bustamante J, Ku C-L, Casanova J-L. Primary immunodeficiencies associated with pneumococcal disease. Curr Opin Allergy Clin Immunol 2003;3:451-9.
17. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46.
18. Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013;381:825-35.
19. Langley JM, Dodds L, Fell D, Langley GR. Pneumococcal and influenza immunization in asplenic persons: a retrospective population-based cohort study 1990-2002. BMC Infect Dis 2010;10:219.
20. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986;314:1593-9.
21. Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev 2009;22:396-414.
22. Halliday E, Winkelstein J, Webster ADB. Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality. J Infect 2003;46:1-8.
23. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000;20:94-100.
24. Quinti I, Soresina A, Guerra A, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol 2011;31:315-22.
25. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a metaanalysis of clinical studies. Clin Immunol 2010;137:21-30.
26. Di Rienzo AG, Van Der Horst C, Finkelstein DM, Frame P, Bozzette SA, Tashima KT. Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. AIDS Res Hum Retroviruses 2002;18:89-94.
27. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98.
28. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009;145:709-27.
29. Malphettes M, Gérard L, Carmagnat M, et al. Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. Clin Infect Dis 2009;49:1329-38.
30. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125:1354-60.
31. Goldacker S, Draeger R, Warnatz K, et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol 2007;124:294-303.
32. Lougaris V, Badolato R, Ferrari S, Plebani A. Hyper immunoglobulinM syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol Rev 2005;203:48-66.
33. Durandy A, Revy P, Imai K, Fischer A. Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects. Immunol Rev 2005;203:67-79.
34. Fischer A. Severe combined immunodeficiencies (SCID). Clin Exp Immunol 2000;122:143-9.
35. Buckley RH. Primary cellular immunodeficiencies. J Allergy Clin Immunol 2002;109:747-57.
36. Stephan JL, Vlekova V, Le Deist F, et al. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr 1993;123:564-72.
37. Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997;130:378-87.
38. Holland SM, De Leo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007;357:1608-19.
39. Freeman AF, Holland SM. The hyper-IgE syndromes. Immunol Allergy Clin North Am 2008;28:277-91.
40. Chandesris M-O, Melki I, Natividad A, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore) 2012;91:e1-19.